Earnings Scheduled For November 24, 2021
Companies Reporting Before The Bell
• Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million.
Earnings Preview For Centogene
Centogene (NASDAQ:CNTG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.
Analysts estimate that Centogene will likely report an Earnings Per Share (EPS) of $-0.55.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Centogene, Twist Join Forces For Custom Test Kits For Rare Diseases
Centogene NV (NASDAQ:CNTG) and Twist Bioscience Corporation (NASDAQ:TWST) have signed a contract to develop and commercialize custom assay…
Centogene, Twist Bioscience Report Contract To Collab On Development, Commercialization Of Custom Assay Kits For Rare Diseases, No Terms Disclosed
Centogene N.V. (NASDAQ:CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, and Twist Bioscience Corporation (NASDAQ:TWST), a Company enabling
Centogene Q2 Revenues €51.9M, Up 434% YoY; Commercial OVID-19 Testing Revenues €42.3M, Up From €2.1M YoY
Revenues of €51.9 million in Q2 2021, a 434% increase compared to €9.7 million in Q2 2020; Revenues from the Company’s Pharma and Diagnostics segments (“Core
Earnings Scheduled For September 7, 2021
Companies Reporting Before The Bell
• Cheetah Mobile (NYSE:CMCM) is projected to report earnings for its second quarter.
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.
CENTOGENE Reports Shareholders Approve All Resolutions From Annual General Meeting
Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company’s Annual
CENTOGENE Announces Investor Event Jun. 22 At 9:00 a.m. EDT
Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeutics
Focuses on leveraging its unique rare disease-centric